Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Immunome (IMNM) Financials

Immunome logo
$21.53 +1.87 (+9.51%)
Closing price 05/20/2026 04:00 PM Eastern
Extended Trading
$21.60 +0.07 (+0.35%)
As of 04:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Immunome

Annual Income Statements for Immunome

This table shows Immunome's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -10 -18 -25 -38 -107 -293 -212
Consolidated Net Income / (Loss)		 -10 -18 -25 -37 -107 -293 -212
Net Income / (Loss) Continuing Operations		 -10 -18 -25 -37 -107 -293 -212
Total Pre-Tax Income 		-10 -18 -25 -37 -107 -293 -212
Total Operating Income		 -10 -12 -25 -37 -110 -306 -224
Total Gross Profit		 0.00 0.00 0.00 0.00 14 9.04 6.94
Total Revenue		 0.00 0.00 0.00 0.00 14 9.04 6.94
Operating Revenue		 - - - 0.00 14 9.04 6.94
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 10 12 25 37 124 315 231
Selling, General & Admin Expense		 1.53 4.78 11 14 20 33 44
Research & Development Expense		 8.82 7.49 14 23 104 282 187
Total Other Income / (Expense), net		 -0.10 -5.58 0.49 0.01 2.72 13 12
Interest Expense		 0.10 0.04 0.01 -0.01 -2.72 -13 -12
Basic Earnings per Share		 ($9.55) ($5.26) ($2.14) ($3.09) ($5.38) ($5.00) ($2.43)
Weighted Average Basic Shares Outstanding		 1.09M 3.39M 11.54M 12.13M 19.84M 58.64M 87.35M
Diluted Earnings per Share		 ($9.55) ($5.26) ($2.14) ($3.09) ($5.38) ($5.00) ($2.43)
Weighted Average Diluted Shares Outstanding		 1.09M 3.39M 11.54M 12.13M 19.84M 58.64M 87.35M
Weighted Average Basic & Diluted Shares Outstanding		 1.09M 3.39M 12.13M 12.22M 59.69M 86.95M 113.13M

Quarterly Income Statements for Immunome

This table shows Immunome's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.35 -93 -129 -36 -47 -80 -42 -43 -57 -70 -54
Consolidated Net Income / (Loss)		 -4.35 -93 -129 -36 -47 -80 -42 -43 -57 -70 -54
Net Income / (Loss) Continuing Operations		 -4.35 -93 -129 -36 -47 -80 -42 -43 -57 -70 -54
Total Pre-Tax Income 		-4.35 -93 -129 -36 -47 -80 -42 -43 -57 -70 -54
Total Operating Income		 -4.63 -95 -132 -40 -51 -83 -45 -46 -60 -73 -59
Total Gross Profit		 3.57 3.83 1.03 2.36 2.91 2.74 2.93 4.02 0.00 - 0.00
Total Revenue		 3.57 3.83 1.03 2.36 2.91 2.74 2.93 4.02 0.00 - 0.00
Operating Revenue		 3.57 3.83 1.03 2.36 2.91 2.74 2.93 4.02 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 8.20 98 133 42 53 86 48 50 60 73 59
Selling, General & Admin Expense		 4.38 8.04 6.01 6.98 9.53 10 11 10 11 12 13
Research & Development Expense		 3.82 90 127 35 44 75 37 40 49 61 46
Total Other Income / (Expense), net		 0.29 2.02 2.81 3.89 3.42 2.72 3.00 3.08 2.68 2.96 5.49
Interest Expense		 -0.29 -2.02 -2.81 -3.89 -3.42 -2.72 -3.00 -3.08 -2.68 -2.96 -5.49
Basic Earnings per Share		 ($0.36) ($4.21) ($2.51) ($0.60) ($0.78) ($1.11) ($0.52) ($0.50) ($0.65) ($0.76) ($0.48)
Weighted Average Basic Shares Outstanding		 12.20M 19.84M 51.54M 59.94M 60.21M 58.64M 79.41M 87.01M 87.96M 87.35M 113.14M
Diluted Earnings per Share		 ($0.36) ($4.21) ($2.51) ($0.60) ($0.78) ($1.11) ($0.52) ($0.50) ($0.65) ($0.76) ($0.48)
Weighted Average Diluted Shares Outstanding		 12.20M 19.84M 51.54M 59.94M 60.21M 58.64M 79.41M 87.01M 87.96M 87.35M 113.14M
Weighted Average Basic & Diluted Shares Outstanding		 42.73M 59.69M 59.97M 60.05M 62.42M 86.95M 87.01M 87.05M 91.71M 113.13M 113.25M

Annual Cash Flow Statements for Immunome

This table details how cash moves in and out of Immunome's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.94 37 9.46 -29 78 45 510
Net Cash From Operating Activities		 -9.60 -12 -18 -29 -7.57 -111 -191
Net Cash From Continuing Operating Activities		 -9.60 -12 -18 -29 -7.57 -111 -191
Net Income / (Loss) Continuing Operations		 -10 -18 -25 -37 -107 -293 -212
Consolidated Net Income / (Loss)		 -10 -18 -25 -37 -107 -293 -212
Depreciation Expense		 0.62 0.76 0.76 0.42 0.46 1.57 2.47
Amortization Expense		 - - 0.00 0.21 -0.24 -2.36 -2.35
Non-Cash Adjustments To Reconcile Net Income		 0.02 6.16 2.95 5.33 87 168 37
Changes in Operating Assets and Liabilities, net		 0.21 -1.21 2.78 2.24 12 15 -15
Net Cash From Investing Activities		 -0.23 -0.59 -0.08 -0.25 -30 -85 61
Net Cash From Continuing Investing Activities		 -0.23 -0.59 -0.08 -0.25 -30 -85 61
Purchase of Property, Plant & Equipment		 -0.23 -0.59 -0.08 -0.25 -0.83 -7.17 -9.69
Acquisitions		 - - - - 0.00 -46 -6.25
Purchase of Investments		 - - - 0.00 -39 -187 -123
Divestitures		 - - - 0.00 9.28 0.00 0.00
Sale and/or Maturity of Investments		 - - - - 0.00 155 200
Net Cash From Financing Activities		 11 50 28 0.03 116 241 640
Net Cash From Continuing Financing Activities		 11 50 28 0.03 116 241 640
Issuance of Common Equity		 0.00 39 29 0.00 125 20 46
Other Financing Activities, net		 -0.22 -0.19 -0.80 0.03 -8.63 221 594

Quarterly Cash Flow Statements for Immunome

This table details how cash moves in and out of Immunome's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 52 8.04 171 -104 -9.76 -12 114 -114 129 381 -71
Net Cash From Operating Activities		 -8.61 -17 -11 -23 -34 -42 -53 -49 -41 -48 -59
Net Cash From Continuing Operating Activities		 -8.61 -17 -11 -23 -34 -42 -53 -49 -41 -48 -59
Net Income / (Loss) Continuing Operations		 -4.35 -93 -129 -36 -47 -80 -42 -43 -57 -70 -54
Consolidated Net Income / (Loss)		 -4.35 -93 -129 -36 -47 -80 -42 -43 -57 -70 -54
Depreciation Expense		 0.11 0.15 0.16 0.55 0.41 0.45 0.61 0.64 0.59 0.63 0.60
Amortization Expense		 0.39 -0.74 -0.43 -0.23 -1.31 -0.39 -0.70 -1.12 -0.67 0.15 0.15
Non-Cash Adjustments To Reconcile Net Income		 1.09 84 114 9.50 12 33 5.64 6.42 6.57 18 7.87
Changes in Operating Assets and Liabilities, net		 -5.85 -8.14 4.51 2.91 2.31 5.21 -17 -12 10 3.22 -13
Net Cash From Investing Activities		 -0.04 -30 -37 -82 24 9.76 5.09 -64 124 -4.00 -12
Net Cash From Continuing Investing Activities		 -0.04 -30 -37 -82 24 9.76 5.09 -64 124 -4.00 -12
Purchase of Property, Plant & Equipment		 -0.04 -0.35 -2.16 -2.34 -1.54 -1.13 -3.67 -0.91 -1.12 -4.00 -3.00
Acquisitions		 - - -35 -6.66 -4.36 -0.25 -6.25 - - - -9.01
Sale and/or Maturity of Investments		 - - 0.00 - 30 85 15 60 125 - 0.00
Net Cash From Financing Activities		 61 55 219 0.69 0.31 20 162 -0.06 45 433 -0.14
Net Cash From Continuing Financing Activities		 61 55 219 0.69 0.31 20 162 -0.06 45 433 -0.14
Issuance of Debt		 - - 230 - - - 173 - - - 0.00
Issuance of Common Equity		 61 64 - - - 20 0.00 - - - 0.00
Other Financing Activities, net		 -0.13 -8.50 -11 0.69 0.31 0.09 -10 -0.06 -0.51 605 -0.14

Annual Balance Sheets for Immunome

This table presents Immunome's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 5.06 45 58 24 149 240 683
Total Current Assets		 3.12 43 57 23 145 221 661
Cash & Equivalents		 2.54 40 49 20 99 143 653
Short-Term Investments		 - - - 0.00 39 74 0.00
Prepaid Expenses		 0.58 3.13 7.41 2.33 6.56 4.04 7.30
Plant, Property, & Equipment, net		 1.70 1.53 0.86 0.68 2.07 10 15
Total Noncurrent Assets		 0.24 0.10 0.43 0.72 1.76 8.79 7.78
Other Noncurrent Operating Assets		 0.24 0.10 0.43 0.72 1.76 8.79 7.78
Total Liabilities & Shareholders' Equity		 5.06 45 58 24 149 240 683
Total Liabilities		 1.80 3.18 9.74 7.39 29 59 49
Total Current Liabilities		 1.67 3.04 9.73 7.33 22 54 45
Accounts Payable		 0.55 1.19 3.08 2.40 3.31 14 3.34
Accrued Expenses		 0.67 1.37 6.65 4.93 8.03 33 42
Current Deferred Revenue		 - - - 0.00 10 6.94 0.00
Total Noncurrent Liabilities		 0.13 0.14 0.01 0.06 6.83 4.77 3.86
Other Noncurrent Operating Liabilities		 0.11 - 0.01 0.06 1.34 4.77 3.86
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -36 41 48 17 120 181 634
Total Preferred & Common Equity		 -36 41 48 17 120 181 634
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -36 41 48 17 120 181 634
Common Stock		 0.93 96 127 133 343 697 1,363
Retained Earnings		 -37 -54 -79 -116 -223 -516 -728
Accumulated Other Comprehensive Income / (Loss)		 - - - 0.00 0.02 0.06 0.00

Quarterly Balance Sheets for Immunome

This table presents Immunome's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 31 48 41 93 320 296 257 343 296 299 620
Total Current Assets		 29 47 40 91 313 284 244 323 277 280 594
Cash & Equivalents		 27 44 38 91 270 165 156 258 144 273 583
Short-Term Investments		 - - - - 40 113 85 60 124 0.00 0.00
Prepaid Expenses		 2.16 2.11 1.11 0.77 3.62 5.93 3.91 5.81 9.40 7.29 12
Plant, Property, & Equipment, net		 0.70 0.92 1.20 1.17 4.30 6.10 7.17 11 11 12 17
Total Noncurrent Assets		 0.60 0.66 0.71 0.58 2.13 5.84 5.69 8.61 7.83 7.89 8.40
Other Noncurrent Operating Assets		 0.60 0.66 0.71 0.58 2.13 5.84 5.69 8.61 7.83 7.89 8.40
Total Liabilities & Shareholders' Equity		 31 48 41 93 320 296 257 343 296 299 620
Total Liabilities		 7.46 34 32 87 34 42 42 36 27 35 31
Total Current Liabilities		 7.37 25 26 23 31 40 40 31 23 31 27
Accounts Payable		 3.14 3.31 3.70 2.79 7.18 7.05 3.52 9.13 4.66 6.15 5.53
Accrued Expenses		 4.23 3.31 5.03 3.37 11 20 26 18 18 25 22
Current Deferred Revenue		 - 18 18 17 13 13 9.68 4.02 0.00 0.00 0.00
Total Noncurrent Liabilities		 0.09 9.42 5.71 64 3.41 2.48 2.46 4.77 4.14 4.01 3.69
Other Noncurrent Operating Liabilities		 0.09 0.00 0.00 61 1.21 2.48 2.46 4.77 4.14 4.01 3.69
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 - - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 23 14 9.34 6.08 286 254 215 307 269 264 589
Total Preferred & Common Equity		 23 14 9.34 6.08 286 254 215 307 269 264 589
Preferred Stock		 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 23 14 9.34 6.08 286 254 215 307 269 264 589
Common Stock		 131 134 135 136 638 642 650 865 870 922 1,371
Retained Earnings		 -108 -120 -126 -130 -352 -388 -436 -557 -601 -658 -782
Accumulated Other Comprehensive Income / (Loss)		 - - - - 0.00 0.00 0.07 -0.00 -0.02 0.00 0.00

Annual Metrics And Ratios for Immunome

This table displays calculated financial ratios and metrics derived from Immunome's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - 91,710,277.00
DEI Adjusted Shares Outstanding		 - - - - - - 91,710,277.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -2.32
Growth Metrics		 - - - - - - -
Profitability Metrics		 - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -7.24 -8.58 -18 -26 -77 -214 -157
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -63.96% -118.16% -24.73%
Earnings before Interest and Taxes (EBIT)		 -10 -18 -25 -37 -110 -306 -224
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.73 -17 -24 -36 -109 -307 -224
Valuation Ratios		 - - - - - - -
Leverage & Solvency		 - - - - - - -
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -9.94 -15 -23 -62 -196 -174
Efficiency Ratios		 - - - - - - -
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.72 2.08 -1.04 -3.67 -18 -36 -19
Increase / (Decrease) in Invested Capital		 0.00 1.36 -3.12 -2.63 -15 -18 17
Book Value per Share		 ($32.57) $3.92 $3.98 $1.37 $2.81 $2.90 $6.92
Tangible Book Value per Share		 ($32.57) $3.92 $3.98 $1.37 $2.81 $2.90 $6.92
Total Capital		 3.26 42 48 17 120 181 634
Total Debt		 0.00 0.50 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.13 0.00 0.00 0.00 0.00 0.00
Net Debt		 -2.54 -39 -49 -20 -138 -217 -653
Capital Expenditures (CapEx)		 0.23 0.59 0.08 0.25 0.83 7.17 9.69
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.09 0.46 -2.32 -5.01 -15 -50 -38
Debt-free Net Working Capital (DFNWC)		 1.46 40 47 15 123 167 616
Net Working Capital (NWC)		 1.46 40 47 15 123 167 616
Net Nonoperating Expense (NNE)		 3.20 9.25 7.07 11 30 79 56
Net Nonoperating Obligations (NNO)		 -2.54 -39 -49 -20 -138 -217 -653
Total Depreciation and Amortization (D&A)		 0.62 0.76 0.76 0.63 0.22 -0.80 0.12
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($5.26) ($2.14) ($3.09) ($5.38) ($5.00) ($2.43)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 10.66M 11.54M 12.13M 19.84M 58.64M 87.35M
Adjusted Diluted Earnings per Share		 $0.00 ($5.26) ($2.14) ($3.09) ($5.38) ($5.00) ($2.43)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 10.66M 11.54M 12.13M 19.84M 58.64M 87.35M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($5.26) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 3.39M 12.13M 12.22M 59.69M 86.95M 113.13M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.24 -8.58 -18 -26 -77 -214 -157
Debt Service Ratios		 - - - - - - -
Payout Ratios		 - - - - - - -

Quarterly Metrics And Ratios for Immunome

This table displays calculated financial ratios and metrics derived from Immunome's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - 91,710,277.00 113,133,199.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 91,710,277.00 113,133,199.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.76 -0.48
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% -56.47% -44.55% -18.37% -28.44% 184.35% 69.84% -100.00% - -100.00%
EBITDA Growth		 50.89% -1,165.31% -2,966.71% -606.70% -1,143.63% 12.95% 66.26% -18.33% -17.11% - -30.96%
EBIT Growth		 45.71% -1,115.53% -2,859.05% -593.04% -990.48% 12.34% 66.26% -16.17% -19.03% - -32.92%
NOPAT Growth		 45.71% -1,115.53% -2,859.05% -593.04% -990.48% 12.34% 66.26% -16.17% -19.03% - -32.92%
Net Income Growth		 49.08% -1,089.75% -2,932.60% -550.03% -984.00% 13.37% 67.84% -20.14% -21.99% - -29.30%
EPS Growth		 52.00% -557.81% -617.14% -30.43% -116.67% 73.63% 79.28% 16.67% 16.67% - 7.69%
Operating Cash Flow Growth		 -13.78% -161.24% -146.21% -312.79% -296.65% -140.91% -374.98% -111.14% -18.56% - -10.52%
Free Cash Flow Firm Growth		 2,354.59% -1,728.99% -541.59% -257.61% -222.47% 22.19% 54.38% -78.95% 38.12% - -27.75%
Invested Capital Growth		 -2,017.30% -397.55% 21.03% 15.69% 70.17% -97.91% 57.75% 105.03% 65.43% - 158.77%
Revenue Q/Q Growth		 -16.37% 7.32% -73.11% 129.74% 23.10% -5.91% 6.87% 37.22% -100.00% - 0.00%
EBITDA Q/Q Growth		 26.37% -2,203.26% -39.69% 70.06% -29.57% -61.23% 46.05% -5.00% -28.23% - 18.74%
EBIT Q/Q Growth		 19.75% -1,943.02% -39.77% 69.76% -26.28% -64.23% 46.20% -4.13% -29.39% - 18.57%
NOPAT Q/Q Growth		 19.75% -1,943.02% -39.77% 69.76% -26.28% -64.23% 46.20% -4.13% -29.39% - 18.57%
Net Income Q/Q Growth		 21.81% -2,031.97% -39.79% 72.10% -30.39% -70.38% 48.11% -4.22% -32.40% - 22.98%
EPS Q/Q Growth		 21.74% -1,069.44% 40.38% 76.10% -30.00% -42.31% 53.15% 3.85% -30.00% - 36.84%
Operating Cash Flow Q/Q Growth		 -51.98% -102.68% 36.02% -109.46% -46.03% -23.10% -26.14% 6.89% 18.00% - -22.28%
Free Cash Flow Firm Q/Q Growth		 274.20% -166.82% -91.68% 67.11% -190.78% 57.55% -12.39% -29.00% -0.54% - 15.12%
Invested Capital Q/Q Growth		 -190.82% 78.41% -32.17% -1.58% -2.89% -43.27% 71.78% 112.10% -806.65% - 131.31%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% - 0.00%
EBITDA Margin		 -115.99% -2,489.28% -12,883.77% -1,678.85% -1,767.15% -3,028.16% -1,528.64% -1,169.69% 0.00% - 0.00%
Operating Margin		 -129.96% -2,473.94% -12,857.05% -1,692.43% -1,736.15% -3,030.31% -1,525.50% -1,157.61% 0.00% - 0.00%
EBIT Margin		 -129.96% -2,473.94% -12,857.05% -1,692.43% -1,736.15% -3,030.31% -1,525.50% -1,157.61% 0.00% - 0.00%
Profit (Net Income) Margin		 -121.88% -2,421.17% -12,584.26% -1,528.00% -1,618.56% -2,930.94% -1,423.10% -1,080.87% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Interest Burden Percent		 93.78% 97.87% 97.88% 90.28% 93.23% 96.72% 93.29% 93.37% 95.54% - 90.74%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -150.60% -156.45% -154.98% -199.56% -276.36% -194.63% -69.21% -81.20% -93.04% - -50.14%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -14,827.65% 0.00% - -3,059.50%
Operating Return on Assets (OROA)		 -21.41% -401.88% -886.55% -108.11% -100.47% -140.94% -50.38% -49.19% 0.00% - 0.00%
Return on Assets (ROA)		 -20.08% -393.31% -867.74% -97.60% -93.67% -136.32% -47.00% -45.93% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -150.60% -156.45% -154.98% -199.56% -276.36% -194.63% -69.21% -81.20% -93.04% - -50.14%
Return on Equity Simple (ROE_SIMPLE)		 -361.39% 0.00% -81.25% -103.45% -142.08% 0.00% -66.78% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.24 -66 -93 -28 -35 -58 -31 -33 -42 -51 -42
NOPAT Margin		 -90.97% -1,731.76% -8,999.93% -1,184.70% -1,215.31% -2,121.22% -1,067.85% -810.33% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.87% -33.29% -20.83% -5.12% -7.10% -12.47% -3.32% -3.98% -5.99% - -2.73%
Return On Investment Capital (ROIC_SIMPLE)		 - -55.27% - - - -32.06% -10.17% -12.08% -15.95% -8.04% -7.06%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 122.72% 210.14% 583.58% 295.18% 327.35% 381.52% 365.35% 250.11% 0.00% - 0.00%
R&D to Revenue		 107.24% 2,363.80% 12,373.47% 1,497.25% 1,508.80% 2,748.79% 1,260.15% 1,007.50% 0.00% - 0.00%
Operating Expenses to Revenue		 229.96% 2,573.94% 12,957.05% 1,792.43% 1,836.15% 3,130.31% 1,625.50% 1,257.61% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.63 -95 -132 -40 -51 -83 -45 -46 -60 -73 -59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.14 -95 -133 -40 -51 -83 -45 -47 -60 -72 -59
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 16.77 3.81 5.16 2.86 4.09 3.66 1.91 3.01 3.86 - 4.20
Price to Tangible Book Value (P/TBV)		 16.77 3.81 5.16 2.86 4.09 3.66 1.91 3.01 3.86 - 4.20
Price to Revenue (P/Rev)		 10.00 32.62 116.16 67.29 86.68 73.32 53.50 64.28 105.31 - 616.24
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 438.56 0.00 - 315.62
Enterprise Value to Revenue (EV/Rev)		 1.10 22.76 91.74 41.48 62.97 49.28 24.49 42.99 77.14 - 471.12
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 3.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -4.04 -1.16 -1.18 -1.20 -1.50 -1.18 -1.06 -1.04 -1.07 - -1.00
Leverage Ratio		 4.24 1.26 1.23 1.28 1.58 1.29 1.12 1.13 1.16 - 1.07
Compound Leverage Factor		 3.98 1.24 1.20 1.16 1.48 1.25 1.04 1.06 1.11 - 0.98
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 -0.43 6.46 24.05 9.02 10.52 3.46 8.22 15.69 14.54 - 46.75
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.96 6.63 10.18 7.12 6.17 4.08 10.49 12.13 8.90 - 21.68
Quick Ratio		 3.92 6.33 10.07 6.98 6.07 4.00 10.30 11.72 8.67 - 21.26
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 77 -52 -99 -33 -95 -40 -45 -58 -59 -68 -58
Operating Cash Flow to CapEx		 -23,927.78% -5,002.58% -516.17% -998.17% -2,220.08% -3,735.35% -1,447.61% -5,458.67% -3,629.93% - -1,953.30%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.16 0.16 0.07 0.06 0.06 0.05 0.03 0.04 0.03 - 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 10.87 10.18 4.86 2.95 2.43 1.48 1.43 1.47 1.03 - 0.29
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -85 -18 -24 -25 -25 -36 -10 1.23 -8.72 -19 5.99
Invested Capital Turnover		 -0.23 -1.28 -0.46 -0.40 -0.18 -0.33 -0.64 -1.08 -0.57 - -1.91
Increase / (Decrease) in Invested Capital		 -81 -15 6.43 4.56 59 -18 14 26 17 17 16
Enterprise Value (EV)		 11 319 1,164 447 638 446 268 541 747 - 1,892
Market Capitalization		 102 457 1,473 726 878 663 585 809 1,019 - 2,474
Book Value per Share		 $0.50 $2.81 $4.78 $4.23 $3.58 $2.90 $3.53 $3.09 $3.03 $6.92 $5.20
Tangible Book Value per Share		 $0.50 $2.81 $4.78 $4.23 $3.58 $2.90 $3.53 $3.09 $3.03 $6.92 $5.20
Total Capital		 6.08 120 286 254 215 181 307 269 264 634 589
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -91 -138 -310 -278 -240 -217 -317 -268 -273 -653 -583
Capital Expenditures (CapEx)		 0.04 0.35 2.16 2.34 1.54 1.13 3.67 0.91 1.12 4.00 3.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -22 -15 -27 -34 -36 -50 -25 -13 -24 -38 -16
Debt-free Net Working Capital (DFNWC)		 68 123 283 244 205 167 292 255 248 616 567
Net Working Capital (NWC)		 68 123 283 244 205 167 292 255 248 616 567
Net Nonoperating Expense (NNE)		 1.10 26 37 8.12 12 22 10 11 15 19 12
Net Nonoperating Obligations (NNO)		 -91 -138 -310 -278 -240 -217 -317 -268 -273 -653 -583
Total Depreciation and Amortization (D&A)		 0.50 -0.59 -0.28 0.32 -0.90 0.06 -0.09 -0.49 -0.08 0.78 0.75
Debt-free, Cash-free Net Working Capital to Revenue		 -219.17% -108.92% -214.05% -314.99% -351.64% -556.03% -228.47% -107.09% -249.61% - -393.42%
Debt-free Net Working Capital to Revenue		 670.16% 876.54% 2,227.85% 2,266.17% 2,019.07% 1,847.49% 2,672.64% 2,022.04% 2,567.20% - 14,119.48%
Net Working Capital to Revenue		 670.16% 876.54% 2,227.85% 2,266.17% 2,019.07% 1,847.49% 2,672.64% 2,022.04% 2,567.20% - 14,119.48%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.36) ($4.21) ($2.51) ($0.60) ($0.78) ($1.11) ($0.52) ($0.50) ($0.65) ($0.76) ($0.48)
Adjusted Weighted Average Basic Shares Outstanding		 12.20M 19.84M 51.54M 59.94M 60.21M 58.64M 79.41M 87.01M 87.96M 87.35M 113.14M
Adjusted Diluted Earnings per Share		 ($0.36) ($4.21) ($2.51) ($0.60) ($0.78) ($1.11) ($0.52) ($0.50) ($0.65) ($0.76) ($0.48)
Adjusted Weighted Average Diluted Shares Outstanding		 12.20M 19.84M 51.54M 59.94M 60.21M 58.64M 79.41M 87.01M 87.96M 87.35M 113.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 42.73M 59.69M 59.97M 60.05M 62.42M 86.95M 87.01M 87.05M 91.71M 113.13M 113.25M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.24 -66 -93 -28 -35 -58 -31 -33 -42 -51 -42
Normalized NOPAT Margin		 -90.97% -1,731.76% -8,999.93% -1,184.70% -1,215.31% -2,121.22% -1,067.85% -810.33% 0.00% - 0.00%
Pre Tax Income Margin		 -121.88% -2,421.17% -12,584.26% -1,528.00% -1,618.56% -2,930.94% -1,423.10% -1,080.87% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Immunome Inc. (IMNM) continues to post large operating losses as it advances its biotechnology programs. Across the quarters from 2022 through 2025, revenue remains small or zero in most periods, while research and development (R&D) and selling, general & administrative (SG&A) expenses dominate, leading to ongoing negative earnings. The company’s liquidity story improved in late 2025 thanks to substantial financing activity, but that liquidity is largely the result of external fundraising rather than improved cash generation from operations.

Key takeaways

  • Significant financing inflow in Q4 2025: net cash from continuing financing activities was about $432.8 million, delivering a substantial boost to cash balances.
  • Healthy near-term liquidity from investing activity in Q3 2025: net cash from continuing investing activities was about $123.9 million, driven by sale/maturity of investments.
  • Another solid financing uptick in Q1 2025: net cash from continuing financing activities around $162.2 million helped support balance sheet liquidity.
  • Q4 2025 ended with a strong net increase in cash of about $380.8 million, aided by financing activities, contributing to a higher ending cash balance.
  • Cash balance remained sizable through 2025, with cash and equivalents in the low-to-mid hundreds of millions level in mid-2025, supporting liquidity for ongoing operations and potential milestones.
  • Revenue remains very limited or zero in several quarters (e.g., Q3 2025 and Q4 2025), with only modest gains in a few periods (e.g., Q2 2025 and Q1 2025).
  • Non-cash adjustments and other income/expense items can offset a portion of losses in cash flow, but they do not eliminate the operating cash burn.
  • Ongoing net losses: net income attributable to common shareholders was -$69.9 million in Q4 2025 and -$57.5 million in Q3 2025, continuing a trend of annual quarterly losses.
  • Very high R&D and operating expenses relative to revenue: Q4 2025 R&D was $60.8 million and SG&A was $12.1 million, with total operating expenses of $72.9 million, yielding a sizable operating loss.
  • Cash burn from operations: net cash from continuing operating activities was negative in every reported quarter in 2025 (e.g., -$47.95 million in Q4 2025, -$40.51 million in Q3 2025, -$49.40 million in Q2 2025, -$53.06 million in Q1 2025), indicating ongoing operating cash burn.
  • Rising share count and dilution concerns: it appears weighted-average shares outstanding grew to about 113 million in Q4 2025, which can dilute earnings per share even when financing inflows occur.
  • Negative retained earnings and ongoing equity dynamics: retained earnings were deeply negative in 2025 quarters, signaling accumulated deficits and ongoing reliance on equity financing.
05/21/26 03:22 AM ETAI Generated. May Contain Errors.

Immunome Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Immunome's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Immunome's net income appears to be on an upward trend, with a most recent value of -$212.39 million in 2025, rising from -$10.44 million in 2019. The previous period was -$292.96 million in 2024. See Immunome's forecast for analyst expectations on what's next for the company.

Immunome's total operating income in 2025 was -$224.11 million, based on the following breakdown:
  • Total Gross Profit: $6.94 million
  • Total Operating Expenses: $231.05 million

Over the last 6 years, Immunome's total revenue changed from $0.00 in 2019 to $6.94 million in 2025, a change of 694,100,000.0%.

Immunome's total liabilities were at $48.85 million at the end of 2025, a 17.3% decrease from 2024, and a 2,619.7% increase since 2019.

In the past 6 years, Immunome's cash and equivalents has ranged from $2.54 million in 2019 to $653.48 million in 2025, and is currently $653.48 million as of their latest financial filing in 2025.

Over the last 6 years, Immunome's book value per share changed from -32.57 in 2019 to 6.92 in 2025, a change of -121.2%.


Related Companies

Financial statements for NASDAQ:IMNM last updated on 5/17/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel